Abstract
Interferons (IFNs) are a subclass of lymphocyte-released cytokines that interfere with intracellular viral replication. These drugs are classified into three groups: IFN type 1 (IFN-α, IFN-β, and IFN-ω), IFN type 2 (IFN-γ), and IFN type 3 (IFN-λ). Despite numerous trials, IFN therapy has yet to conclusively demonstrate superiority in the treatment of various pulmonary diseases. In addition to the FDA-approved and ongoing investigational uses for IFN therapy, there is a debate regarding the appropriate dosage of these agents. A retrospective literature review is moving experts towards low-dose therapies in nearly every application of IFN therapy. It is speculated that known and unknown toxicity may limit the beneficial effects of IFN therapy.
Keywords: Asthma, idiopathic pulmonary fibrosis, influenza, interferon.
Current Respiratory Medicine Reviews
Title:The Use of Interferons in Respiratory Diseases
Volume: 9 Issue: 5
Author(s): Ori-Michael J. Benhamou, Miriam Jacobs, Jonathan Drew, Shahar Geva, Maor Waldman and Or Kalchiem-Dekel
Affiliation:
Keywords: Asthma, idiopathic pulmonary fibrosis, influenza, interferon.
Abstract: Interferons (IFNs) are a subclass of lymphocyte-released cytokines that interfere with intracellular viral replication. These drugs are classified into three groups: IFN type 1 (IFN-α, IFN-β, and IFN-ω), IFN type 2 (IFN-γ), and IFN type 3 (IFN-λ). Despite numerous trials, IFN therapy has yet to conclusively demonstrate superiority in the treatment of various pulmonary diseases. In addition to the FDA-approved and ongoing investigational uses for IFN therapy, there is a debate regarding the appropriate dosage of these agents. A retrospective literature review is moving experts towards low-dose therapies in nearly every application of IFN therapy. It is speculated that known and unknown toxicity may limit the beneficial effects of IFN therapy.
Export Options
About this article
Cite this article as:
Benhamou J. Ori-Michael, Jacobs Miriam, Drew Jonathan, Geva Shahar, Waldman Maor and Kalchiem-Dekel Or, The Use of Interferons in Respiratory Diseases, Current Respiratory Medicine Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/1573398X10666140520004706
DOI https://dx.doi.org/10.2174/1573398X10666140520004706 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineutrophil Cytoplasmic Antibody in Lupus Nephritis: Correlation with Clinicopathological Characteristics and Disease Activity
Current Rheumatology Reviews Regulatory Roles of the Ubiquitin-Proteasome System in Cardiomyocyte Apoptosis
Current Molecular Medicine Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Neurofibrillary Tangles and Senile Plaques in Alzheimers Brains are Associated with Reduced Capillary Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase
Current Neurovascular Research Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery
Current Pharmaceutical Design Concurrence of Talaromycosis and Kaposi Sarcoma in an HIV-Infected Patient: A Case Report
Current HIV Research Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Antiplatelet Effects of Bioactive Compounds Present in Tomato Pomace
Current Drug Targets Innate and Adaptive Immune Responses in Chronic HCV Infection
Current Drug Targets L-PRP/L-PRF in Esthetic Plastic Surgery, Regenerative Medicine of the Skin and Chronic Wounds
Current Pharmaceutical Biotechnology Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?
Current Vascular Pharmacology Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Autoantibodies as Biomarkers for ANCA-Associated Vasculitides
Current Immunology Reviews (Discontinued)